CSIMarket Company Name, Ticker, Suppliers, else..
 
Arrowhead Pharmaceuticals Inc   (NASDAQ: ARWR)
 

Arrowhead Pharmaceuticals Inc's Suppliers Performance

ARWR's Supply Chain



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 
ARWR Costs vs Sales of Suppliers Growth

• More on ARWR Suppliers






Arrowhead Pharmaceuticals Inc's Comment on Supply Chain


The company relies primarily on third-party manufacturers for the production of clinical supplies and commercial products, including REDEMPLO and other drug candidates. Its internal manufacturing capabilities are limited to oligonucleotide drug substances at the clinical stage, with no internal production of drug products or biologics. The company has expanded its GMP drug substance manufacturing capacity through a facility in Verona, Wisconsin. Due to the limited number of manufacturers supplying synthetic oligonucleotides, risks such as synthesis failures and contamination could affect supply and development timelines. The company has established third-party agreements for manufacturing REDEMPLO's drug substance and drug product in preparation for its commercial launch in 2025. Some manufacturing partners may require funding for capital improvements to support scale-up.

Arrowhead Pharmaceuticals Inc's Comment on Supply Chain


The company relies primarily on third-party manufacturers for the production of clinical supplies and commercial products, including REDEMPLO and other drug candidates. Its internal manufacturing capabilities are limited to oligonucleotide drug substances at the clinical stage, with no internal production of drug products or biologics. The company has expanded its GMP drug substance manufacturing capacity through a facility in Verona, Wisconsin. Due to the limited number of manufacturers supplying synthetic oligonucleotides, risks such as synthesis failures and contamination could affect supply and development timelines. The company has established third-party agreements for manufacturing REDEMPLO's drug substance and drug product in preparation for its commercial launch in 2025. Some manufacturing partners may require funding for capital improvements to support scale-up.







ARWR's vs. Suppliers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)



COMPANY NAME MARKET CAP REVENUES INCOME EMPLOYEES
Arrowhead Pharmaceuticals Inc 9,600.59 669.50 -272.13 711
SUBTOTAL 0.00 0.00 0.00 -


Sources: Arrowhead Pharmaceuticals Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Arrowhead Pharmaceuticals Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.